You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Maytansine

Showing 1 - 25 of 127
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-Positive Solid Tumors Trial in Guangzhou (BAT8001)

Unknown status
  • HER2-Positive Solid Tumors
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Dec 5, 2019

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

Not yet recruiting
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • (no location specified)
Nov 7, 2023

Trastuzumab Emtansine as Therapy in Chinese HER2 Positive

Not yet recruiting
  • Breast Cancer
  • Trastuzumab emtansine
  • (no location specified)
Jul 13, 2023

HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy Trial (Trastuzumab Emtansine for Injection, Pyrotinib Maleate

Not yet recruiting
  • HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
  • Trastuzumab Emtansine for Injection
  • Pyrotinib Maleate Tablets
  • (no location specified)
Sep 30, 2022

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

Metastatic Solid Tumor, Brain Metastases Trial in Houston (Trastuzumab emtansine, Tucatinib)

Not yet recruiting
  • Metastatic Solid Tumor
  • Brain Metastases
  • Houston, Texas
    M D Anderson Cancer Center
Dec 30, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

Recruiting
  • Advanced Breast Cancer
  • +2 more
  • Trastuzumab Emtansine (T-DM1)
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023

Endometrial Cancer Trial in New Haven (IMGN853)

Recruiting
  • Endometrial Cancer
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 10, 2022

Trastuzumab Emtansine in HER2-positive Breast Cancer Residual

Recruiting
  • Breast Cancer
  • Trastuzumab emtansine
  • Prato, Firenze, Italy
  • +27 more
Mar 2, 2023

Adenocarcinoma Gastric, Gastrooesophageal Cancer Trial in Worldwide (Ramucirumab (CYRAMZA®), Tusamitamab ravtansine (SAR408701))

Recruiting
  • Adenocarcinoma Gastric
  • Gastrooesophageal Cancer
  • Ramucirumab (CYRAMZA®)
  • Tusamitamab ravtansine (SAR408701)
  • Bruxelles, Belgium
  • +22 more
Jan 16, 2023

NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Maastricht, Limburg, Netherlands
  • +4 more
Nov 7, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 16, 2022

Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer Trial (Trastuzumab,

Recruiting
  • Brain Metastases
  • +2 more
  • Saint Louis, Missouri
  • +1 more
Nov 8, 2022

Solid Tumor Cancers, Lung Cancer, Bladder Cancer Trial in United States (ado-trastuzumab emtansine)

Recruiting
  • Solid Tumor Cancers
  • +3 more
  • ado-trastuzumab emtansine
  • Basking Ridge, New Jersey
  • +6 more
Mar 1, 2022

Non-squamous NSCLC Trial in Worldwide (Tusamitamab ravtansine)

Recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • Tusamitamab ravtansine
  • Edegem, Belgium
  • +18 more
Aug 3, 2022

Tumor Trial (Tusamitamab ravtansine)

Not yet recruiting
  • Neoplasm
  • Tusamitamab ravtansine
  • (no location specified)
Jun 22, 2022

Breast Cancer Trial (Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F

Not yet recruiting
  • Breast Cancer
  • Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
  • Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
  • (no location specified)
Feb 22, 2023

Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,

Recruiting
  • Salivary Gland Cancer
  • HER2 Gene Mutation
  • Ado-trastuzumab (T) emtansine (T-DM1)
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 2, 2023

Breast Cancer, Heart Failure Trial in Canada, Russian Federation (Trastuzumab, Pertuzumab, Trastuzumab emtansine)

Recruiting
  • Breast Cancer
  • Heart Failure
  • Hamitlon, Ontario, Canada
  • +3 more
Jun 21, 2022

Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer Trial in Rotterdam (Tusamitamab ravtansine)

Not yet recruiting
  • Metastatic Lung Cancer
  • +2 more
  • Tusamitamab ravtansine
  • Rotterdam, Netherlands
    Erasmus MC
Jan 26, 2023

Tumors Trial in France, Moldova, Republic of (Anetumab ravtansine (BAY94-9343))

Completed
  • Neoplasms
  • Anetumab ravtansine (BAY94-9343)
  • Caen, France
  • +7 more
Jul 6, 2021

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Anetumab Ravtansine
  • +2 more
  • Orange, California
  • +22 more
Oct 22, 2022

Mesothelin Positive, Stage III NSCLC AJCC v7, Stage IIIA NSCLC AJCC v7 Trial in Phoenix, Jacksonville, Rochester (Anetumab

Terminated
Has Results
  • Mesothelin Positive
  • +4 more
  • Anetumab Ravtansine
  • +2 more
  • Phoenix, Arizona
  • +2 more
Jan 5, 2023